Business Of Biotech The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.
Aug 5, 2024
Kristin Yarema, Ph.D., the newly-appointed CEO of Poseida Therapeutics, dives into the transformative world of CAR T therapeutics. She envisions a future where allogeneic therapies make life-saving treatments widely accessible. Kristin shares her journey from academia to biotech, emphasizing the benefits of strategic collaborations with companies like Astellas and Roche. The conversation highlights the innovative convertible CAR T approach and the ongoing challenges in scalable production for autoimmune diseases, underscoring the critical role of partnerships in advancing cancer treatment.
AI Snips
Chapters
Transcript
Episode notes
From Academia to Consulting
- Kristin Yarema's career began in chemical engineering but she felt drawn to broader impact.
- Consulting at McKinsey offered diverse projects with top pharma companies, sharpening her business acumen.
Consulting for Early Career Scientists
- Consider consulting for early career exposure to diverse biotech projects and companies.
- This builds valuable pattern recognition and business skills, complementing academic expertise.
Balancing Left and Right Brain
- Dr. Yarema pursued a dual degree in chemical engineering and English literature at Stanford.
- She sought a balance between technical and artistic pursuits, ultimately prioritizing biopharma for impact.